Orthopaedics and Trauma
Volume 23, Issue 2 , Pages 117-121 , April 2009

Is infection inevitable in some arthroplasty patients?

References 

  1. Imman R, Gallegos K, Brause B, Redecha P, Christian C. Clinical and microbiological features of prosthetic joint infection. Am J Med. 1984;77:47–53
  2. Harris W. The problem is osteolysis. Clin Orthop. 1995;311:46–50
  3. Tunney M, Patrick S, Gorman S. Improved detection of infection in hip replacements. A currently underestimated problem. J Bone Joint Surg. 1998;80B:568–575
  4. Lidgren L, Knutson K, Stefansdottir A. Infection of prosthetic joints. Best Pract Res Clin Rheumatol. 2003;17:209–218
  5. Malik M, Bayat A, Jury F, Kay P, Ollier W. Genetic susceptibility to total hip arthroplasty failure-positive association with mannose-binding lectin. J Arthroplasty. 2007;22:265–270
  6. Cooke G, Hill A. Genetics of susceptibility to human infectious disease. Nat Rev Genet. 2001;2:967–977
  7. Minnema B, Vearncombe M, Augustin A, Gollish J, Simor A. Risk factors for surgical-site infection following primary total knee arthroplasty. Infect Control Hosp Epidemiol. 2004;25:477–480
  8. Honstettre A, Mege J, Lina G, Aubaniac J, Drancourt M. Relationship of relapsing hip prosthesis infection by Staphylococcus aureus with gamma interferon deficiency. J Clin Microbiol. 2003;41:5344–5346
  9. Bjornsson GL, Thorsteinsson L, Gudmundsson KO, Jonsson H, Gudmundsson S, Gudbjornsson B. Inflammatory cytokines in relation to adrenal response following total hip replacement. Scand J Immunol. 2007;65:99–105
  10. Di Cesare PE, Chang E, Preston CF, Liu CJ. Serum interleukin-6 as a marker of periprosthetic infection following total hip and knee arthroplasty. J Bone Joint Surg: American Edition. 2005;87:1921–1927
  11. Kolundzic R, Orlic D, Trkulja V, Pavelic K, Troselj KG. Single nucleotide polymorphisms in the interleukin-6 gene promoter, tumor necrosis factor-alpha gene promoter, and transforming growth factor-beta1 gene signal sequence as predictors of time to onset of aseptic loosening after total hip arthroplasty: preliminary study. J Orthop Sci. 2006;11:592–600
  12. Konttinen YT, Xu JW, Waris E, et al. Interleukin-6 in aseptic loosening of total hip replacement prostheses. Clin Exp Rheumatol. 2002;20:485–490
  13. Janeway C, Travers P. 3rd edn. Non-adaptive host response to infection. Immunobiology: The immune system in health and disease. 9. New York: Garland Publishing; 1997;20-9:22
  14. Thiel S, Holmskov U, Hviid L, Laursen SB, Jensenius J. The concentration of C-type lectin, mannan-binding protein, in human plasma increases during an acute phase response. Clin Exp Immunol. 1992;90:31–35
  15. Tsutsumi A, Takahashi R, Suminda T. Mannose binding lectin: genetics and autoimmune disease. Autoimmun Rev. 2005;4:364–372
  16. Sastry K, Herman G, Day L, Deignan E, Bruns G, Morton C. The human mannose binding protein gene. Exon structure reveals its evolutionary relationship to a human pulmonary surfactant gene and localisation to chromosome 10. J Exp Med. 1989;170:1175–1189
  17. Madsen H, Garred P, Kurtzhals J, Lamm L, Ryder L, Thiel S. A new frequent allele is the missing link in the structural polymorphism of the human mannan binding protein. Immunogenetics. 1994;40:37–44
  18. Suminya M, Super M, Tabona P, Levinsky R, Arai T, Turner M. Molecular basis of opsonic defect in immunodeficient children. Lancet. 1991;337:1569–1570
  19. Lipscombe R, Suminya M, Hill A, Lau Y, Levinsky R, Summerfield J. High frequencies in African and non African populations of independent mutations in the mannose binding protein gene. Hum Mol Genet. 1992;1:709–715
  20. Madsen H, Satz M, Hogh B, Svejgaard A, Garred P. Different molecular events result in low protein levels of mannan-binding lectin in populations from southeast Africa and South America. J Immunol. 1998;161:3169–3175
  21. Garred P, Larsen F, Seyforth J, Fujita R, Madsen H. Mannose binding lectin and its genetic variants. Genes Immun. 2006;7:85–94
  22. Eisen D, Minchiton R. Impact of mannose binding lectin on susceptibility to infectious diseases. Clin Infect Dis. 2003;37:1496–1505
  23. Peterson S, Thiel S, Jensenius JC. The mannan binding lectin pathway of complement activation: biology and disease association. Mol Immunol. 2001;38:133–149
  24. Garred P, Thiel S, Madsen H, Ryder L, Jensenius JC, Svejgaard A. Gene frequency and partial protein characterization of an allelic variant of mannan binding protein associated with low serum concentrations. Clin Exp Immunol. 1992;90:517–521
  25. Garred P, Madsen H, Kurtzhals J, Lamm L, Thiel S, Hey A. Diallelic polymorphisms may explain variations of blood concentrations of mannan-binding protein in Eskimos, but not in black Africans. Eur J Immunogenet. 1992;19:403–412
  26. Minchiton R, Dean M, Clark T, Heatley S, Mulligan C. Analysis of the relationship between mannose binding lectin (MBL) genotype, MBL levels and function in Australian blood donor population. Scand J Immunol. 2002;56:630–641
  27. Madsen H, Garred P, Thiel S. Interplay between promoter and structural gene variants control basal serum level of mannan-binding protein. J Immunol. 1995;155:3013–3020
  28. Jacobsen S, Madsen H, Klarlund M, et al. The influence of mannose binding lectin polymorphisms on disease outcome in early polyarthritis. J Rheumatol. 2001;28:935–942
  29. Rector A, Lemey P, Laffut W. MBL gene polymorphisms in ulcerative colitis and Crohn’s disease. Genes Immun. 2002;2:323
  30. Garred P, Madsen H, Halberg P. MBL polymorphisms and susceptibility to infection in systemic lupus erythematosus. Arthritis Rheum. 1999;42:2145
  31. Tsutsumi A, Sasaki K, Wakamiya N, Ichikawa K, Atsumi T, Ohtani K. Mannose binding lectin gene: polymorphisms in Japanese patients with systemic Lupus erythematosus, rheumatoid arthritis and Sjogrens syndrome. Genes Immun. 2001;2:99–104
  32. Neth O, Jack D, Johnson M, Klein N, Turner M. Enhancement of complement activation and opsonophagocytosis by complexes of mannose-binding lectin with mannose-binding lectin-associated serine protease after binding to Staphylococcus aureus. J Immunol. 2002;169:4430–4436
  33. Neth O, Jack D, Dodds A. Mannose-binding lectin binds to a range of clinically relevant microorganisms and promotes complement deposition. Infect Immun. 2000;68:688–693
  34. Miller M, Seals J, Kaye R, Levitsky R. A familial, plasma associated defect of phagocytosis: a new cause of recurrent bacterial infection. Lancet. 1968;ii:60–63
  35. Super M, Lu J, Thiel S, Levinsky R, Turner M. Association of low levels of mannan binding protein with a common defect of opsonisation. Lancet. 1989;334:1236–1239
  36. Turner M. Mannose-binding lectin: the pluripotent molecule of the innate immune system. Immunol Today. 1996;17:532–540
  37. Roy S, Knox K, Segal S. MBL genotype and risk of invasive pneumococcal disease: a case controlled study. Lancet. 2002;359:1569–1573
  38. Kronberg G, Weis N, Madsen H. Variant mannose-binding lectin alleles are not associated with susceptibility to or outcome of invasive pneumococcal infection in randomly included patients. J Infect Dis. 2002;185:1517–1520
  39. Klein N. Mannose-binding lectin: do we need it?. Mol Immunol. 2005;42:919–924
  40. Casanova J, Abel L. Human mannose-binding lectin in immunity: Friend, foe or both?. J Exp Med. 2004;10:1295–1299
  41. Fidler K, Wilson P, Davies J, Turner M, Peters M, Klein N. Increased incidence and severity of the systemic inflammatory response syndrome in patients deficient in mannose binding lectin. Intensive Care Med. 2004;30:1438–1445
  42. Ytting H, Christensen I, Jensenius J, Thiel S, Nielsen H. Preoperative mannan-binding lectin pathway and prognosis in colorectal cancer. Cancer Immunol Immunother. 2005;54:265–272
  43. Siassi M, Hohenberger W, Riese J. Mannan-binding lectin (MBL) serum levels and post-operative infections. Biochem Soc Trans. 2003;31:774–775
  44. Malchau H, Herberts P, Ahnfelt L. Prognosis of total hip replacement in Sweden. Follow up of 92, 675 operations performed 1978–1990. Acta Orthop Scan. 1993;64:497
  45. Thiel S, Frederiksen P, Jensenius J. Clinical manifestations of manna binding lectin deficiency. Mol Immunol. 2006;43:86–96
  46. Wooley P, Fitzgerald R, Song Z. Proteins bound to polyethylene components in patients who have aseptic loosening after total joint arthroplasty. J Bone Joint Surg: American Edition. 1999;81:616
  47. Valdimarsson H, Stefansson M, Vikingdottir T, et al. Reconstitution of opsonizing activity by infusion of mannan-binding lectin (MBL) to MBL deficient humans. Scand J Immunol. 1998;48:116–123
  48. Valdimarsson H, Vikingdottir T, Bang P, et al. Human plasma-derived mannose binding lectin: a phase I safety and pharmacokinetic study. Scand J Immunol. 2004;59:97–102
  49. Vorup-Jensen T, Sorensen E, Jensen U. Recombinant expression of human mannan binding lectin. Int Immunopharmacol. 2001;1:677–687
  50. Jensenius J, Jensen P, McGuire K, Larsen J, Thiel S. Recombinant mannan-binding lectin (MBL) for therapy. Biochem Soc Trans. 2003;31:763–767
  51. Garred P, Pressler T, Lanng S, et al. Mannose-binding lectin (MBL) therapy in an MBL-deficient patient with severe cystic fibrosis lung disease. Pediatr Pulmonol. 2002;33:201–207

PII: S1877-1327(08)00199-1

doi: 10.1016/j.mporth.2008.12.004

Orthopaedics and Trauma
Volume 23, Issue 2 , Pages 117-121 , April 2009

Article Tools

* Image Usage & Resolution